Literature DB >> 24657523

Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.

Alessandro Poggi1, Alessandra Musso2, Irene Dapino2, Maria Raffaella Zocchi3.   

Abstract

Tumor microenvironment represents the site where the tumor tries to survive and escape from immune system-mediated recognition. Indeed, to proliferate tumor cells can divert the immune response inducing the generation of myeloid derived suppressor cells and regulatory T cells which can limit the efficiency of effector antitumor lymphocytes in eliminating neoplastic cells. Many components of the tumor microenvironment can serve as a double sword for the tumor and the host. Several types of fibroblast-like cells, which herein we define mesenchymal stromal cells (MSC), secrete extracellular matrix components and surrounding the tumor mass can limit the expansion of the tumor. On the other hand, MSC can interfere with the immune recognition of tumor cells producing immunoregulatory cytokines as transforming growth factor (TGF)ß, releasing soluble ligands of the activating receptors expressed on cytolytic effector cells as decoy molecules, affecting the correct interaction among lymphocytes and tumor cells. MSC can also serve as target for the same anti-tumor effector lymphocytes or simply impede the interaction between these lymphocytes and neoplastic cells. Thus, several evidences point out the role of MSC, both in epithelial solid tumors and hematological malignancies, in regulating tumor cell growth and immune response. Herein, we review these evidences and suggest that MSC can be a suitable target for a more efficient anti-tumor therapy.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibrocytes; Immunosuppression; MSC; NK; NKG2D; TAF

Mesh:

Substances:

Year:  2014        PMID: 24657523     DOI: 10.1016/j.imlet.2014.03.001

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  50 in total

1.  Role of MSC-derived galectin 3 in the AML microenvironment.

Authors:  Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-04-12       Impact factor: 4.739

Review 2.  HIF-1 at the crossroads of hypoxia, inflammation, and cancer.

Authors:  Kuppusamy Balamurugan
Journal:  Int J Cancer       Date:  2015-04-07       Impact factor: 7.396

3.  PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth.

Authors:  Parul Gupta; Stephen E Wright; Sanjay K Srivastava
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

Review 4.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

5.  Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.

Authors:  Lucia Borriello; Rie Nakata; Michael A Sheard; G Esteban Fernandez; Richard Sposto; Jemily Malvar; Laurence Blavier; Hiroyuki Shimada; Shahab Asgharzadeh; Robert C Seeger; Yves A DeClerck
Journal:  Cancer Res       Date:  2017-07-07       Impact factor: 12.701

6.  The role of the immune system in brain metastasis.

Authors:  Adam T Leibold; Gina N Monaco; Mahua Dey
Journal:  Curr Neurobiol       Date:  2019-07

7.  Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.

Authors:  Hong-Wei Wu; Michael A Sheard; Jemily Malvar; G Esteban Fernandez; Yves A DeClerck; Laurence Blavier; Hiroyuki Shimada; Charles P Theuer; Richard Sposto; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2019-05-08       Impact factor: 12.531

8.  Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy.

Authors:  Mark J de Keijzer; Daniel J de Klerk; Lianne R de Haan; Robert T van Kooten; Leonardo P Franchi; Lionel M Dias; Tony G Kleijn; Diederick J van Doorn; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

Review 9.  Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

Authors:  Charlie Garnett-Benson; James W Hodge; Sofia R Gameiro
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

Review 10.  Emerging principles of brain immunology and immune checkpoint blockade in brain metastases.

Authors:  Jawad Fares; Ilya Ulasov; Peter Timashev; Maciej S Lesniak
Journal:  Brain       Date:  2021-05-07       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.